AbCellera Biologics Inc. (ABCL)
| Market Cap | 1.66B +170.1% |
| Revenue (ttm) | 79.21M +242.7% |
| Net Income | -143.96M |
| EPS | -0.48 |
| Shares Out | 305.26M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,471,804 |
| Open | 5.33 |
| Previous Close | 5.29 |
| Day's Range | 5.16 - 5.54 |
| 52-Week Range | 1.97 - 6.52 |
| Beta | 1.03 |
| Analysts | Strong Buy |
| Price Target | 10.43 (+86.4%) |
| Earnings Date | May 11, 2026 |
About ABCL
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lil... [Read more]
Financial Performance
In 2025, AbCellera Biologics's revenue was $75.13 million, an increase of 160.56% compared to the previous year's $28.83 million. Losses were -$146.41 million, -10.10% less than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for ABCL stock is "Strong Buy." The 12-month stock price target is $10.43, which is an increase of 86.40% from the latest price.
News
AbCellera Biologics Transcript: Bank of America Global Healthcare Conference 2026
The company has evolved from a discovery partner to a clinical-stage developer, leveraging its proprietary antibody platform and significant capital to advance a differentiated pipeline. Lead asset ABCL635 targets NK3R with promising safety and efficacy, while additional programs in autoimmunity and oncology are advancing with strategic confidentiality.
AbCellera price target raised to $8 from $7 at Stifel
Stifel raised the firm’s price target on AbCellera (ABCL) to $8 from $7 and keeps a Buy rating on the shares. The firm believes that the disclosure of preliminary safety,…
AbCellera Biologics Q1 Earnings Call Highlights
AbCellera Biologics NASDAQ: ABCL said its first quarter of 2026 was marked by progress in its internal drug pipeline, including interim Phase 1 data for its lead program, ABCL635, and continued prepar...
AbCellera Biologics options imply 9.7% move in share price post-earnings
Pre-earnings options volume in AbCellera (ABCL) Biologics is 4.7x normal with calls leading puts 5:3. Implied volatility suggests the market is anticipating a move near 9.7%, or 52c, after results…
AbCellera Biologics Earnings Call Transcript: Q1 2026
Strong Q1 2026 liquidity and pipeline progress, highlighted by ABCL635's phase I data and phase II advancement for non-hormonal VMS treatment. Revenue doubled year-over-year, R&D investment increased, and net loss narrowed. Top-line phase II data expected Q3 2026.
AbCellera Biologics Earnings release: Q1 2026
AbCellera Biologics released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
AbCellera Biologics Quarterly report: Q1 2026
AbCellera Biologics has published its Q1 2026 quarterly earnings report on May 11, 2026.
AbCellera Biologics Slides: Q1 2026
AbCellera Biologics has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 11, 2026.
AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635.
AbCellera to Present at Upcoming Investor Conferences in May and June 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at Upcoming Investor Conferences in May and June 2026.
AbCellera initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of AbCellera (ABCL) with an Overweight rating and $7 price target
AbCellera Biologics Proxy statement: Proxy filing
AbCellera Biologics filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
AbCellera Biologics Proxy statement: Proxy filing
AbCellera Biologics filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
AbCellera Biologics Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference
The company has transitioned from a partnership-driven model to advancing its own pipeline, with a focus on challenging antibody targets and a strong liquidity position. Lead asset ABCL635 targets hot flashes in menopausal women, with key phase II data expected in Q3 and potential expansion into oncology-related indications.
AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call.
AbCellera initiated with a Buy at JonesResearch
JonesResearch analyst Debanjana Chatterjee initiated coverage of AbCellera (ABCL) with a Buy rating and $11 price target AbCellera’s validated antibody discovery platform has advanced 19 molecules int...
AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026.
AbCellera Biologics Transcript: 2026 KeyBanc Capital Markets Healthcare Forum
A robust antibody-based drug discovery platform supports a growing pipeline, with lead asset ABCL635 in phase II targeting menopausal hot flashes and potential expansion to cancer therapy-induced symptoms. In-house manufacturing and strong financial backing enable flexibility and sustained development.
AbCellera Biologics Transcript: TD Cowen 46th Annual Health Care Conference
The company has evolved into a biotech with robust antibody discovery and manufacturing capabilities, advancing a pipeline led by ABCL635 for menopausal VMS, which is differentiated by safety and dosing convenience. Phase II data for ABCL635 is expected in Q3, with rapid expansion into oncology and additional assets progressing toward clinical trials.
AbCellera Biologics Earnings Call Transcript: Q4 2025
Transitioned to a clinical-stage biotech, expanded pipeline to four clinical/IND-enabling programs, and ended 2025 with $700M liquidity. Revenue rose to $75M, net loss narrowed to $146M, and key clinical readouts are expected in 2026.
AbCellera Biologics Annual report: Q4 2025
AbCellera Biologics has published its Q4 2025 annual report on February 24, 2026.
AbCellera Biologics Earnings release: Q4 2025
AbCellera Biologics released its Q4 2025 earnings on February 24, 2026, summarizing the period's financial results.
AbCellera Biologics Slides: Q4 2025
AbCellera Biologics has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 24, 2026.
AbCellera reports FY25 EPS (49c) vs. (55c) last year
Reports FY25 revenue $75.1M vs. $28.8M last year. “In 2025, AbCellera (ABCL) successfully delivered on all its corporate priorities, transitioned to a clinical-stage biotech company, and ended the yea...
AbCellera Reports Full Year 2025 Business Results
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Full Year 2025 Business Results.